Japan’s AKP Takes Over Artisan To Progress ART-123
This article was originally published in PharmAsia News
Japan's Asahi Kasei Pharma announced Nov. 22 that its acquisition of Massachusetts-based Artisan Pharma, a company it spun out in 2006.
You may also be interested in...
Eli Lilly & Co. announced Oct. 25 that it is ending its ten-year relationship with Xigris, withdrawing the sepsis drug from all markets and ceasing further clinical trials.
Artisan Pharma and Singapore-based A-Bio Pharma have established a relationship under which the Asian firm will provide process development, scale-up and manufacturing support for Artisan's investigational recombinant protein ART-123, the firms announced Sept. 17
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.